Introduction 6 de marzo de 2026
El texto subrayado se agregaría a la ley vigente. El texto tachado se eliminaría.
- House Minnesota House of Representatives House Members and Staff House Members Leadership Staff Employment Who Represents Me? Committees Committee List Committee Roster Upcoming Meetings Standing Committee Schedule Minutes Committee Deadlines Offices Chief Clerk Fiscal Analysis House Research Public Information Sergeant-at-Arms Caucuses - DFL/GOP Other Information House Journal House Rules Joint Rules Educational Programs Pronunciation Guide Address Spreadsheet
- Senate Minnesota Senate Senators and Staff Senators Leadership Staff Employment Who Represents Me? Committees Committee List Committee Roster Upcoming Meetings Standing Committee Schedule Committee Deadlines Offices Secretary of the Senate Senate Counsel, Research & Fiscal Analysis Caucuses - DFL/GOP Other Information Senate Journal Senate Rules Joint Rules Educational Programs Address Labels Subscriptions
- Joint Joint Department, Offices, and Commissions Joint Legislative Offices Legislative Budget Office Legislative Coordinating Commission (LCC) Legislative Reference Library Office of the Legislative Auditor Office of the Revisor of Statutes Commissions Legislative-Citizen Commission on MN Resources Legislative Commission on Pensions & Retirement Lessard-Sams Outdoor Heritage Council More... More Information Joint Offices Directory Joint Offices Staff Accessibility Legacy Amendment
- Schedules Schedules, Calendars, and Legislative Business House House Schedules Order of Business Calendar for the Day Supplemental Calendar for the Day Fiscal Calendar Senate Senate Schedules Order of Business Senate Calendar General Orders of the Day Joint Combined Upcoming Meetings Broadcast TV Schedule Committee Deadlines
- Committees Legislative Committees House Committee List Committee Roster Upcoming Meetings Standing Committee Schedule Minutes Senate Committee List Committee Roster Upcoming Meetings Standing Committee Schedule Joint Joint Committees & Task Forces Committee Deadlines Bills In Conference Committee Side by Side Comparisons
- Bills Bills House Bill Search & Status (House) Bill Introductions Bill Summaries Act Summaries Fiscal Tracking Sheets Senate Bill Search & Status (Senate) Bill Introductions Bill Summaries Act Summaries Fiscal Tracking Sheets Joint Bill Search & Status MyBills Side by Side Comparisons Bills In Conference Committee Vetoes Current Session Laws
- Law Statutes, Laws, and Rules Statutes Keyword Search Current Statutes Statutes by Topic (Index) Statutes Archive Session Laws Keyword Search Current Session Laws Session Laws by Topic (Index) Session Laws Archive Session Laws Changed (Table 1) Statutes Changed (Table 2) Administrative Rules Keyword Search Current Rules Rules by Topic (Index) Rules Archive Minnesota Rule Status State Register Other Legal Materials Minnesota Constitution State Constitutional Amendments Court Rules
- Multimedia Multimedia - Audio, Video, Broadcast TV, News, & Photos House Live Video Audio Webcast Schedule Audio & Video Archives Session Daily Photos Senate Live Video Audio Webcast Schedule Audio & Video Archives Senate Media Services Photos Joint Combined Media Page Legislative Media Archive Broadcast TV Schedule Commission Audio/Video
- Publications Legislative Research, Reports & Information Office Research & Reports House Fiscal Analysis House Research Senate Counsel Publications Legislative Auditor Revisor Publications Legislative Reference Library News House Session Daily Senate Media Services Senate Information Legislators Roster Member Guide Legislative History Legislative History Guide Legislators Past & Present House Journal Senate Journal Legislative Time Capsule Vetoes Notable Documents Fiscal Review Minnesota Issues Guides New Laws Books & reports
Office of the Revisor of Statutes
Revisor Menu- Retrieve by number Document type Statutes Laws Rules Bills GO
- Statutes
- Laws
- Rules
- Court Rules
- Constitution
- Revisor's Office Revisor Intranet Attorney Drafting Areas Staff Directory Office Duties Publications Educational Seminars Employment Openings Order Publications
- Search Law by Keyword
- Bills
- 94th Legislature (2025 - 2026)
- HF4064
- Introduction
HF 4064
Introduction - 94th Legislature (2025 - 2026)
Posted on 03/18/2026 11:49 a.m.
KEY:Bill Text Versions
| Engrossments | ||
|---|---|---|
| Introduction PDF | Posted on 03/06/2026 |
1.6 1.7 1.8 1.9 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 2.24 2.25 2.26 2.27 2.28 2.29 2.30 2.31 2.32 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19
3.20 3.21 3.22 3.23
A bill for an act
relating to health; directing the commissioner of health to study and report on
activities to support innovations in cell and gene therapy to treat rare diseases;
requiring a report; appropriating money.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
Section 1. new text begin STUDY AND REPORT ON ACTIVITIES TO SUPPORT INNOVATIONS
IN CELL AND GENE THERAPIES TO TREAT RARE DISEASES.
new text end
new text begin Subdivision 1. new text end
new text begin Legislative intent. new text end
new text begin
The legislature finds that the development of cell and
gene therapies offers significant promise to treat and potentially cure a wide range of diseases,
including cancer, rare genetic disorders, and autoimmune conditions. The legislature
recognizes that the state of Minnesota is a national leader in biomedical research and health
care innovation and recognizes the importance of fostering scientific progress and promoting
economic development in cell and gene therapy.
new text end
new text begin Subd. 2. new text end
new text begin State policy. new text end
new text begin
It is the policy of the state of Minnesota to support and encourage
the advancement, commercialization, and clinical translation of new technologies and
applications in the fields of cell and gene therapy. These activities include but are not limited
to research and development activities, workforce training programs, public-private
partnerships, regulatory science initiatives, and infrastructure to support clinical trials and
biomanufacturing.
new text end
new text begin Subd. 3. new text end
new text begin Definitions. new text end
new text begin
(a) For purposes of this section, the following terms have the
meanings given.
new text end
new text begin
(b) "Cell and gene therapy" means a biological product intended to modify or manipulate
the expression of one or more genes or to alter biological properties of living cells for
therapeutic use, including but not limited to gene addition, gene editing, gene silencing,
gene replacement, and cell-based therapies.
new text end
new text begin
(c) "Rare disease" means a disease, disorder, or condition that affects fewer than 200,000
individuals in the United States and is chronic, serious, life-altering, or life-threatening.
new text end
new text begin Subd. 4. new text end
new text begin Study on current capacity and strategies to support innovations. new text end
new text begin
(a) The
commissioner of health, in consultation with the University of Minnesota, the Minnesota
Rare Disease Advisory Council, and other stakeholders, shall conduct a comprehensive
study on the state's current capacity for rare disease cell and gene therapy research,
development, delivery, and access and on strategies to support innovations in rare disease
cell and gene therapy research, development, delivery, and access. The study must include
but is not limited to an assessment of:
new text end
new text begin
(1) the infrastructure and capabilities of other states in cell and gene therapy development
and delivery;
new text end
new text begin
(2) opportunities within existing resources and statutory authority to support innovation
in cell and gene therapies in the state, including alignment with state-funded research
programs, participation in federal grant programs and pilot programs, and coordination with
economic development programs;
new text end
new text begin
(3) current capacity in the state for clinical trials and biomedical research on rare disease
cell and gene therapies, including funding sources, academic partnerships, and industry
presence;
new text end
new text begin
(4) current capacity and future opportunities for biomanufacturing related to cell and
gene therapies;
new text end
new text begin
(5) the ability of health systems to deliver cell and gene therapies, including of facilities
performing infusion therapy or transplants, hospital infrastructure, and necessary support
services;
new text end
new text begin
(6) workforce needs, including the availability of clinical geneticists, gene therapy
specialists, advanced practice providers, and allied health professionals;
new text end
new text begin
(7) policies regarding covering and paying for cell and gene therapies, including policies
under the medical assistance program, policies of commercial payers, value-based payment
models, and potential barriers to access resulting from these policies;
new text end
new text begin
(8) regulatory and administrative factors, including licensing requirements, reporting
requirements, and potential barriers based on existing state policies;
new text end
new text begin
(9) health equity and access issues, including barriers to access experienced by rural and
underserved communities; and
new text end
new text begin
(10) economic impacts and costs, including short-term and long-term costs to health
systems and to society.
new text end
new text begin
(b) In conducting this study, the commissioner must seek input from patients with a rare
disease, caregivers of patients with a rare disease, advocacy groups for patients with a rare
disease, health care providers and clinical experts in genetics and cell and gene therapies,
academic research institutions, payers, pharmacy benefit managers, the biotechnology
industry, the pharmaceutical industry, and other appropriate stakeholders identified by the
commissioner.
new text end
new text begin Subd. 5. new text end
new text begin Report and recommendations. new text end
new text begin
By January 1, 2028, the commissioner shall
submit a report to the legislature that includes:
new text end
new text begin
(1) findings from the study conducted under subdivision 4;
new text end
new text begin
(2) short-term and long-term recommendations for strategic investments by the state,
changes to state policies, and regulatory actions by the state to support the state in leading
on rare disease cell and gene therapies; and
new text end
new text begin
(3) identification of potential federal funding opportunities, public-private partnerships,
and grant programs to support implementation of the recommendations.
new text end
new text begin
The report must also be posted on the Department of Health website.
new text end
Sec. 2. new text begin APPROPRIATION.
new text end
new text begin
$....... in fiscal year 2027 is appropriated from the general fund to the commissioner of
health for a study and report on activities to support innovations in rare disease cell and
gene therapies. This is a onetime appropriation and is available until June 30, 2028.
new text end
- Historical Information
- Employment/Internships
- Visiting the Capitol
- Accessibility
- Frequently Asked Questions
- Who Represents Me?
- House Members
- Senators
- Contact a legislative librarian:
- (651) 296-8338 or Email
- Phone Numbers
- Submit website comments
- House News
- Senate News
- MyBills
- Email Updates & RSS Feeds
Texto oficial de la Legislatura de Minnesota. El formato se adaptó para leerlo en Ratifi.